论文部分内容阅读
目的探讨原发性食管小细胞癌(PESC)的临床疗效。方法回顾性分析我院2010年12月-2012年12月PESC患者122例的临床资料。结果术前采用三野根治术配合全身化疗进行治疗的PESC患者108例设为A1组,患者生存时间5-106个月,平均31.8±5.4个月;只采用手术方法进行治疗的患者14例设为A2组,患者平均生存时间14.1±1.9个月。造成患者死亡的主要原因是肿瘤复发和转移。结论 PESC极不稳定,容易全身早期转移,且很难行有效预后。综合治疗过程中实施辅助化疗,能显著延长生存期。
Objective To investigate the clinical efficacy of primary esophageal small cell carcinoma (PESC). Methods The clinical data of 122 patients with PESC in our hospital from December 2010 to December 2012 were retrospectively analyzed. Results 108 cases of PESC patients treated with Sangen radical surgery combined with systemic chemotherapy before operation were selected as group A1, and the patients survived for 5-106 months with an average of 31.8 ± 5.4 months. In the 14 cases treated only with surgical methods, A2 group, the average survival time of patients was 14.1 ± 1.9 months. The main cause of death in patients with tumor recurrence and metastasis. Conclusions PESC is very unstable, easy to transfer to the whole body early, and it is difficult to achieve effective prognosis. The implementation of adjuvant chemotherapy in the comprehensive treatment can significantly prolong survival.